The study clearly demonstrates that in patients with recurrent high-grade glioma treated with either TMZ or PCV, IDH1/2 mutation and MGMT methylation levels are of prognostic value independent of tumour grade and of other clinical prognostic factors. Here, MGMT is linked to glioma.